‘Transformational’ year for pharmaceutical business

Leeds-based pharmaceutical company, 4D pharma, has reported pre-tax losses of £30.3m (2019: £29.4m) in its final results for the year ended 31 December 2020.

Revenues for the year were £534m, compared to £211m in 2019.

The listed company also records total equity of £28m (2019: £22.3m), cash and cash equivalents (including cash on deposit) of £8.8m (2019: £3.8m) along with loss for the year and total comprehensive income for the year of £25.9m (2019: £23.7m).

Founded in February 2014, 4D pharma specialises in the development of LBPs, an emerging class of drugs.

These drugs are defined as biological products which contain a live organism, such as a bacterium, applicable to the prevention, treatment or cure of a disease.

Among the highlights for the business over the last year were its entry into a proposed merger agreement with Longevity Acquisition Corporation (Longevity), a NASDAQ-listed Special Purpose Acquisition Company (SPAC), and its intention to seek a NASDAQ listing.

4D pharma also completed two fundraises by way of a placing and subscription, raising gross proceeds of approximately £30m.

Professor Axel Glasmacher, chairman, said: “2020 was a transformational year for 4D: We were able to publish first proof-of-concept data for MRx0518 in last-line cancers and to initiate our NASDAQ listing.

“This creates a solid foundation for the next steps towards bringing live biotherapeutics to patients suffering from severe diseases.

“On behalf of the Board I would like to thank everyone at 4D for an exceptional performance under difficult circumstances.”

Duncan Peyton, chief executive officer, added: “4D has made significant progress leading the field in the development of Live Biotherapeutics, and made great strides from a corporate perspective.

“In addition to the data we have generated in the field of oncology, we completed our merger with Longevity and obtained a NASDAQ listing which, together with a concurrent fundraise, provides 4D with approximately $40m of additional capital and a solid financial footing moving forward.

“This puts 4D pharma in a strong position to capitalise on multiple data readouts from our ongoing trials in asthma and oncology as well as facilitating the move into the clinic with our Parkinson’s disease programme.”

Click here to sign up to receive our new South West business news...
Close